CVI Investments, Inc. - 31 Dec 2025 SCHEDULE 13G/A Report for Decoy Therapeutics Inc. (f/k/a Salarius Pharmaceuticals, Inc.) Common Stock, $0.0001 par value per share (DCOY)

Filing Manager
CVI Investments, Inc.
Reporting Manager
CVI Investments, Inc.
Security
Decoy Therapeutics Inc. (f/k/a Salarius Pharmaceuticals, Inc.) Common Stock, $0.0001 par value per share
Symbol
DCOY
Shares outstanding
7,157,222 shares
Disclosed Ownership
708,565 shares
Ownership
9.9%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 14:47:30 UTC
Date of event
31 Dec 2025
Previous filing
18 Nov 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"CVI Investments, Inc. disclosed 9.9% ownership in Decoy Therapeutics Inc. (f/k/a Salarius Pharmaceuticals, Inc.) Common Stock, $0.0001 par value per share (DCOY) on 31 Dec 2025."

Quick Takeaways

  • CVI Investments, Inc. filed SCHEDULE 13G/A for Decoy Therapeutics Inc. (f/k/a Salarius Pharmaceuticals, Inc.) Common Stock, $0.0001 par value per share (DCOY).
  • Disclosed ownership: 9.9%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 18 Nov 2025.
  • Current filing was accepted on 17 Feb 2026, 14:47.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
CVI Investments, Inc. 9.9% 708,565 0 708,565 /s/ Sarah Travis Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
Heights Capital Management, Inc. 9.9% 708,565 0 708,565 /s/ Sarah Travis Sarah Travis, Assistant General Counsel and Assistant Secretary

Sponsored